JP2004521076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004521076A5 JP2004521076A5 JP2002522926A JP2002522926A JP2004521076A5 JP 2004521076 A5 JP2004521076 A5 JP 2004521076A5 JP 2002522926 A JP2002522926 A JP 2002522926A JP 2002522926 A JP2002522926 A JP 2002522926A JP 2004521076 A5 JP2004521076 A5 JP 2004521076A5
- Authority
- JP
- Japan
- Prior art keywords
- thrombomodulin
- analog
- seq
- modified
- linked glycosylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010079274 Thrombomodulin Proteins 0.000 description 6
- 102000012607 Thrombomodulin Human genes 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004989 O-glycosylation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 108700003414 solulin Proteins 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22971400P | 2000-08-31 | 2000-08-31 | |
| US09/938,405 US20020111296A1 (en) | 2000-08-31 | 2001-08-23 | Thrombomodulin analogs for use in recovery of spinal cord injury |
| PCT/US2001/041930 WO2002017953A2 (en) | 2000-08-31 | 2001-08-31 | Thrombomodulin analogs for use in recovery of signal cord injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521076A JP2004521076A (ja) | 2004-07-15 |
| JP2004521076A5 true JP2004521076A5 (enExample) | 2008-09-11 |
Family
ID=26923554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002522926A Withdrawn JP2004521076A (ja) | 2000-08-31 | 2001-08-31 | シグナルコード障害の回復に使用するためのトロンボモジュリン類似体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20020111296A1 (enExample) |
| EP (1) | EP1365788B1 (enExample) |
| JP (1) | JP2004521076A (enExample) |
| AT (1) | ATE361755T1 (enExample) |
| AU (2) | AU9322901A (enExample) |
| CA (1) | CA2420900A1 (enExample) |
| DE (1) | DE60128399T2 (enExample) |
| DK (1) | DK1365788T3 (enExample) |
| ES (1) | ES2287161T3 (enExample) |
| IL (2) | IL154600A0 (enExample) |
| NO (1) | NO20030919L (enExample) |
| PT (1) | PT1365788E (enExample) |
| WO (1) | WO2002017953A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006005362A1 (en) * | 2004-07-13 | 2006-01-19 | Paion Deutschland Gmbh | Production of mammalian proteins in plant cells |
| US20060148695A1 (en) * | 2005-01-03 | 2006-07-06 | National Cheng Kung University | Novel angiogenic composition and use thereof |
| US8293710B2 (en) * | 2005-01-03 | 2012-10-23 | Blue Blood Biotech Corp. | Method for treating wounds using an EGF-like domain of thrombomodulin |
| EP1912660A1 (en) * | 2005-08-11 | 2008-04-23 | Medigenes Co., Ltd. | Pharmaceutical composition for the treatment of nerve damage comprising blood plasma or serum |
| EP2014296A1 (en) * | 2007-07-10 | 2009-01-14 | PAION Deutschland GmbH | Novel strategies for increasing the reperfusion in obstructed blood vessel |
| AR067345A1 (es) * | 2007-07-10 | 2009-10-07 | Paion Deutschland Gmbh | Uso de trombomodulina para la preparacion de un medicamento trombolitico |
| US20110144024A1 (en) * | 2008-07-16 | 2011-06-16 | Paion Deutschland Gmbh | Prevention and treatment of radiation injury |
| WO2010006635A1 (en) * | 2008-07-16 | 2010-01-21 | Paion Deutschland Gmbh | Treatment of inflammatory bowel disease |
| NZ702242A (en) | 2012-05-31 | 2016-03-31 | Asahi Kasei Pharma Corp | Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent |
| AU2019347406B9 (en) * | 2018-09-28 | 2023-11-16 | Asahi Kasei Pharma Corporation | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
| US11497795B2 (en) | 2018-09-28 | 2022-11-15 | Asahi Kasei Pharma Corporation | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256770A (en) * | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
| US6063763A (en) * | 1989-04-28 | 2000-05-16 | Schering Aktiengesellschaft | Protease-resistant thrombomodulin analogs |
| US5466668A (en) * | 1989-04-28 | 1995-11-14 | Schering Aktiengesellschaft | Superior thrombomodulin analogs for pharmaceutical use |
| JP3789147B2 (ja) * | 1995-04-11 | 2006-06-21 | 旭化成ファーマ株式会社 | 脊髄損傷後の神経障害に対する治療剤 |
-
2001
- 2001-08-23 US US09/938,405 patent/US20020111296A1/en not_active Abandoned
- 2001-08-31 AT AT01973674T patent/ATE361755T1/de not_active IP Right Cessation
- 2001-08-31 WO PCT/US2001/041930 patent/WO2002017953A2/en not_active Ceased
- 2001-08-31 ES ES01973674T patent/ES2287161T3/es not_active Expired - Lifetime
- 2001-08-31 DE DE60128399T patent/DE60128399T2/de not_active Expired - Fee Related
- 2001-08-31 JP JP2002522926A patent/JP2004521076A/ja not_active Withdrawn
- 2001-08-31 DK DK01973674T patent/DK1365788T3/da active
- 2001-08-31 AU AU9322901A patent/AU9322901A/xx active Pending
- 2001-08-31 IL IL15460001A patent/IL154600A0/xx active IP Right Grant
- 2001-08-31 CA CA002420900A patent/CA2420900A1/en not_active Abandoned
- 2001-08-31 EP EP01973674A patent/EP1365788B1/en not_active Expired - Lifetime
- 2001-08-31 AU AU2001293229A patent/AU2001293229B2/en not_active Ceased
- 2001-08-31 PT PT01973674T patent/PT1365788E/pt unknown
-
2003
- 2003-02-24 IL IL154600A patent/IL154600A/en not_active IP Right Cessation
- 2003-02-27 NO NO20030919A patent/NO20030919L/no not_active Application Discontinuation
- 2003-04-10 US US10/410,195 patent/US20040002446A1/en not_active Abandoned
-
2008
- 2008-08-22 US US12/197,031 patent/US20090143281A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004521076A5 (enExample) | ||
| WO1995025749A3 (en) | Eating suppressant peptides | |
| CA2067744A1 (en) | The human c3b/c4b receptor (cr1) | |
| WO2000024893A3 (en) | Methods and compositions for the prevention and treatment of anemia | |
| EP0055945A3 (en) | Human proinsulin and analogs thereof and method of preparation by microbial polypeptide expression and conversion thereof to human insulin | |
| EP1197220A3 (en) | Therapeutic methods and compositions based on delta proteins and nucleic acids | |
| WO2001081405A3 (en) | Methods and compositions for the prevention and treatment of anemia | |
| ZA892397B (en) | The human c3b/c4b receptor(cr1) | |
| WO2004058147A3 (en) | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof | |
| DE68926679D1 (de) | Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids | |
| JP2005506275A5 (enExample) | ||
| GR3029364T3 (en) | Anti-thrombin polypeptides | |
| JP2004527452A5 (enExample) | ||
| JP2002539827A5 (enExample) | ||
| AU7791398A (en) | Antimicrobial peptides derived from ubiquicidine | |
| EP1281763A3 (en) | Early growth response-1 (EGR-1) transcription factor | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| WO2000069901A3 (en) | Proteins with insulin-like activity useful in the treatment of diabetes | |
| WO2003075944A3 (en) | Interferon beta-like molecules for treatment of stroke | |
| WO2002004487A3 (de) | Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen | |
| CA2391647A1 (en) | Biomolecular complex formed between hyaluronic acid and a biomolecule | |
| MXPA02012308A (es) | Nuevo interferon para el tratamiento de esclerosis multiple. | |
| EP1243595A4 (en) | BH4 FUSIONED POLYPEPTIDES | |
| JP2002539829A5 (enExample) | ||
| CA2368767A1 (en) | Protease resistant flint analogs |